E (c (RGDfK) ) 2

E (c (RGDfK) ) is an αvβ3 integrin-specific binding moiety with tumor targeting properties. Increased uptake of E (c (RGDfK) ) in human ovarian cancer OVCAR-3 xenograft tumors may be useful in cancer research[1].

Product Specifications

CAS Number

[250612-47-6]

UNSPSC

12352209

Target

Integrin

Type

Peptides

Related Pathways

Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/e-c-rgdfk.html

Purity

99.82

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N1)=O)CC(O)=O)=O)=O)CCCNC(N)=N)=O)CCCCNC([C@@H](N)CCC(NCCCC[C@@H]2NC([C@H](NC([C@@H](NC(CNC([C@@H](NC2=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC3=CC=CC=C3)=O)=O)=O)[C@H]1CC4=CC=CC=C4

Molecular Formula

C59H87N19O16

Molecular Weight

1318.44

References & Citations

[1]Polyak D, et al. Development of PEGylated doxorubicin‐E‐[c (RGDfK) 2] conjugate for integrin‐targeted cancer therapy[J]. Polymers for Advanced Technologies, 2011, 22 (1) : 103-113.